Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis. (1st November 2016)

• Record Type: Journal Article
• Authors: Peng, Wan; Qiang, Fu; Peng, Wei; Qian, Zhang; Ke, Zhu; Yi, Lu; Jian, Zhong; Chongrong, Qiu
• Is Part Of: International journal of cardiology. Volume 222(2016)
• Page Start: 119
• Page End: 129
• Publication Date: 2016-11-01
• Subjects: Dyslipidemia -- PCSK9 -- LDL-Cholesterol -- Statins -- Hypercholesterolemia; Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2016.07.239
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Background and objective: Heterozygous familial hypercholesterolemia and dyslipidemia are the predominant causes for cardiovascular disease (CVD). Clinical guidelines for lowering CVD risk have advocated that low density lipoprotein-cholesterol (LDL-C) must be reduced. The primary choice of therapy for controlling lipidemia has been statins, which are not completely effective. Proprotein convertase subtilisin/kexin type-9 (PCSK9), which interferes with LDL clearance from circulation, inversely relates to the LDL-C levels. The loss of statin efficacy is likely due to increased circulating PCSK9 and antibody therapy against PCSK9 has been found to be efficacious in lowering LDL-C. In this study, we evaluated the efficacy of PCSK9-mAbs for lowering LDL-C, in statin non-responsive hypercholesterolemia patients. Study design and methods: PubMed, EMBASE, Scholar, Web of Science and Scopus databases were searched to identify randomized controlled trials of PCSK9 antibody–statin combination vs statin, published till 2015. Two reviewers independently screened the articles, and a collective decision was reached about the included studies in the metaanalysis. Parameters analyzed: change from baseline in LDL-C, high-density lipoprotein cholesterol (HDL-C) and total cholesterol (TC); ApoB and ApoA1 levels. Results: A total of 12 studies with 4909 patients were selected. Overall, add-on therapy with PCSK9-mAb to the ongoing statin therapy was found to achieve greater reduction in LDL-C, ApoB, TC, compared to statin therapy. There were no major treatment emergent adverse effects due to PCSK9-mAb therapy. Conclusions: In adult patients with heterozygous familial hypercholesterolemia and dyslipidemia, PCSK9-mAb therapy in combination with statins was able to achieve the goal of lowering LDL-C. Highlights: Heterozygous familial hypercholesterolemia is a predominant cause for cardiovascular disease. The primary choice of therapy has been statins, which are not completely effective. PCSK9-mAbs have been found to be efficacious in lowering LDL-Cholesterol. In this metaanalysis PCSK9-mAb therapy in combination with statins was found to lower LDL-C, effectively.